Achieve Life Sciences ACHV Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount at other companies
Other financials
Where this comes from
Reported directly by Achieve Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount.
The official record: Achieve Life Sciences’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Achieve Life Sciences's valuation allowance, deferred tax asset, increase (decrease), amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Achieve Life Sciences's valuation allowance, deferred tax asset, increase (decrease), amount?
- Achieve Life Sciences (ACHV) reported valuation allowance, deferred tax asset, increase (decrease), amount of $2.15M in Q4 2025.
- How has Achieve Life Sciences's valuation allowance, deferred tax asset, increase (decrease), amount changed year-over-year?
- Achieve Life Sciences's valuation allowance, deferred tax asset, increase (decrease), amount decreased by 0.0% year-over-year, from $2.15M to $2.15M.
- What is the long-term trend for Achieve Life Sciences's valuation allowance, deferred tax asset, increase (decrease), amount?
- Over 4 years (2021 to 2025), Achieve Life Sciences's valuation allowance, deferred tax asset, increase (decrease), amount has grown at a 3.5% compound annual growth rate (CAGR), from $7.5M to $8.6M.
- What does valuation allowance, deferred tax asset, increase (decrease), amount mean?
- This metric tracks the net change in the valuation allowance established against deferred tax assets. An increase in the allowance suggests reduced confidence in realizing tax benefits, while a decrease suggests improved outlook. It is a vital indicator of the company's assessment of its future tax-shielding capacity.